Navigation Links
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
Date:6/13/2008

Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current

CML and ALL Therapies

COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. XL228 is a small molecule inhibitor of BCR-ABL, SRC, and insulin-like growth factor type 1 receptor (IGF1R), which are associated with cancer cell proliferation, survival, and metastasis. The compound also potently inhibits the T315I mutant form of BCR-ABL, which is resistant to all currently approved inhibitors. Dr. Jorge Cortes, Professor of Medicine, Deputy Chair, Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, and an investigator on the phase 1 trial, presented the data in a poster session (Abstract #1260) at the 13th Congress of the European Hematology Association.

Seventeen subjects have received at least one dose of XL228, of whom 16 had completed Cycle 1 as of May 15, 2008. The trial is evaluating a treatment cycle consisting of 4 weekly 1-hour IV infusions of XL228 at doses ranging from 0.45 mg/kg to 7.2 mg/kg. Thirteen of the 17 subjects (76.5%) have BCR-ABL mutations, including seven (41.2%) with the T315I mutation. At the 3.6 and 7.2 mg/kg doses (either as part of Cohorts 4 and 5 or through dose escalation from a previous cohort), all subjects have demonstrated stable or decreasing white blood cell counts. A CML patient with an F317L BCR-ABL mutation in lymphoid blast crisis experienced
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
2. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
3. Exelixis Announces First Quarter 2008 Financial Results
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
7. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
8. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
9. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... results for the second quarter ended June 30, 2014 ... "In the second quarter, we presented ... International Conference (ATS) demonstrating three novel mechanisms of ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, Inc. ... update on its pipeline and new product development ... to initiate a Phase 2a study of AZ-002 ... for the management of patients with acute repetitive ... Staccato -based product candidates for development - AZ-008 ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... Sept. 17 Pharmasset, Inc.,(Nasdaq: VRUS ) management ... held from September 22-25, 2008 at the Grand Hyatt ... Officer,will provide an overview of the company on Wednesday, ... To access a live webcast of Mr. Price,s ...
... CT Colonography Trial Raise Questions for,Patients, OAK ... CT Colonography Trial, published in the September 18 ... improvements in the technology,s,ability to diagnose intermediate- to ... testing is not as effective in diagnosing small ...
Cached Medicine Technology:Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 3ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 4ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 5
(Date:8/1/2014)... The Cardiovascular Research Foundation (CRF) has announced ... will be presented at next month,s Transcatheter Cardiovascular ... premier educational meeting specializing in interventional cardiovascular medicine, ... at the Walter E. Washington Convention Center in ... TCT often direct the course of patient therapies. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 ... Market Outlook to 2020", provides key market ... market. The report provides value, in millions ... average prices (in US dollars) within market ... Ultrasonic Generators and Argon Plasma Coagulation Generators. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 In today’s ... overall development of an individual. Hence, these methods need ... and employability skills can be inculcated. In this age ... boost to these conventional methods. Thus, learning management systems ... methodologies. , As of now, these are proving ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Women who serve ... alcohol than their civilian peers, a new study suggests. ... to consume alcohol. However, these researchers found that women ... men. This may be due to concerns about sexual ... use is tightly linked to sexual assault, both within ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
Breaking Medicine News(10 mins):Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Women in Military Drink Less Than Civilians, Report Shows 2Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2
... Structural biologists at Cold Spring Harbor Laboratory (CSHL) have ... for an allosteric inhibitor in a subtype of the ... cells. The newly discovered binding site -- ... because it is a potential target for drugs that ...
... , THURSDAY, June 16 (HealthDay News) -- ... else is making many people with middle and low ... grown a lot in the U.S., especially since the ... University of Virginia, said in news release from the ...
... By Denise Mann HealthDay Reporter , WEDNESDAY, June ... some people stopped flying out of fear of catching the virus ... new study shows that the "danger zone" for flu transmission is ... had been thought that this hot zone was much larger, according ...
... WEDNESDAY, June 15 (HealthDay News) -- Men who struggle with ... new study suggests. The study, by researchers from ... found that impotence, or erectile dysfunction, was more common among ... frequent the symptoms of the sleep disorder the higher the ...
... HealthDay Reporter , TUESDAY, June 14 (HealthDay News) -- For ... simple as sleeping on their left side, New Zealand researchers ... sleep on their left side had twice the risk of ... increase in risk [from right-sided sleeping] is small for the ...
... used cutting-edge stem cell technology to correct a genetic ... on a promising path that may one day lead ... diseases such as macular degeneration and retinitis pigmentosa which ... in an advance online publication of the journal ...
Cached Medicine News:Health News:CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit 2Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 2Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 3Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 4Health News:Impotence Linked to Restless Legs Syndrome 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 3Health News:Researchers report progress using iPS cells to reverse blindness 2